Axogen Insider Sale of 5,221 Shares Follows 20% Revenue Growth in 2025. Here's What to Know

Core Insights - AxoGen, Inc. specializes in advanced surgical solutions for peripheral nerve injuries, utilizing proprietary biologic and biomaterial technologies to address critical needs in nerve repair and protection [1] - The company reported full-year 2025 revenue of $225.2 million, reflecting a year-over-year increase of 20.2%, with fourth quarter revenue rising 21.3% to $59.9 million [6] - Management is guiding for at least 18% revenue growth in 2026 and expects to achieve free cash flow positivity [6] Transaction Details - On March 16, 2026, Erick Wayne Devinney, Chief Innovation Officer, exercised 17,938 options and sold 5,221 shares for approximately $171,000 [4] - The sale was part of the vesting and immediate settlement of restricted stock units, with shares sold primarily for liquidity and tax obligations [3][5] - The volume of shares sold is smaller than the recent median sale of 10,166 shares, indicating a routine transaction rather than a significant shift in ownership strategy [3] Operational Performance - AxoGen's growth has been broad-based across surgical segments, supported by expanding reimbursement coverage and FDA approval of the Avance product [6] - Adjusted EBITDA improved to $27.9 million for the year, indicating better operating leverage despite a net loss of $15.7 million [6] - The company is focused on translating recent regulatory wins into consistent profitability, which is crucial for long-term investors [7]